Sign In
Buy VNRX
$2.08
-0.240 (-10.34%)
At Close: Jun 03, 2026
Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025
08:30am, Thursday, 27'th Mar 2025
HENDERSON, Nev. , March 27, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it will host a virtual investor event on W
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering
08:00am, Wednesday, 26'th Mar 2025
Up to $2.3 million up front with up to an additional $1.1 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrants HENDERSON, Nev. , March 26, 2025 /PR
VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update
09:30am, Tuesday, 25'th Mar 2025
Conference call to take place on Monday, March 31 at 4:30 p.m. U.S Eastern Time HENDERSON, Nev.
Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry
08:30am, Friday, 21'st Mar 2025
Volition study shows rapid, low-cost, automated Nu.Q® Cancer test accurately detects human cancers at high specificity HENDERSON, Nev. , March 21, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERI
Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer
08:30am, Thursday, 20'th Mar 2025
"Lung Cancer: Hope of a Brighter Tomorrow" illustrates how Nu.Q® Cancer Test aims to transform the diagnosis, treatment and monitoring in the $4 billion lung cancer market1 HENDERSON, Nev. , March 20
Volition Proudly Sponsors the 44th ISICEM Congress
08:30am, Monday, 17'th Mar 2025
Volition to host multiple presentations at the International Symposium on Intensive Care & Emergency Medicine in Brussels, Belgium, from March 18 - 21 HENDERSON, Nev. , March 17, 2025 /PRNewswire/ -
Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems
08:30am, Thursday, 13'th Mar 2025
HENDERSON, Nev. , March 13, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the expansion of its Nu.Q® Vet Cancer Tes
Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test
08:30am, Tuesday, 11'th Mar 2025
Published study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening. The study is expected to be completed by the end of 2025 HENDERSON, Nev.
Nu.Q® Discover tools provide drug developers and scientists with a range of rapid epigenetic profiling assays across pre-clinical and clinical development pathways from discovery to market ready HEN
Volition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference
08:30am, Friday, 28'th Feb 2025
Volition will showcase presentations from Dr. Sue Ettinger, aka Dr. Sue Cancer Vet, Dr. Brett Cordes, DVM, and Dr. Tom Butera, DVM Representatives will also be available at exhibition booth #2943 HEND
Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis
08:30am, Thursday, 06'th Feb 2025
Expanding commercial offering as a bio-partnering model, currently in active discussions with pharmaceutical companies HENDERSON, Nev. , Feb. 6, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERIC
Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025
09:15am, Wednesday, 05'th Feb 2025
HENDERSON, Nev. , Feb. 5, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced it will host a virtual investor event on Fri
Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis
08:30am, Thursday, 30'th Jan 2025
HENDERSON, Nev. , Jan. 30, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which sh
Volition Issues Business Review 2024
08:30am, Wednesday, 08'th Jan 2025
HENDERSON, Nev. , Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outli
VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants
08:00am, Thursday, 12'th Dec 2024
Volition to participate in the upcoming 14th Annual LifeSci Partners Corporate Access Event on January 15 th, 2025 at the Beacon Grand Hotel in San Francisco. HENDERSON, Nev.
